Point72 Asia Singapore Pte. Ltd. Decreases Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Point72 Asia Singapore Pte. Ltd. cut its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 88.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,401 shares of the biopharmaceutical company's stock after selling 62,677 shares during the quarter. Point72 Asia Singapore Pte. Ltd.'s holdings in Emergent BioSolutions were worth $70,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Tidal Investments LLC acquired a new stake in shares of Emergent BioSolutions during the 1st quarter worth $34,000. CWM LLC grew its position in Emergent BioSolutions by 32,706.7% during the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 4,906 shares during the period. Meeder Asset Management Inc. acquired a new stake in Emergent BioSolutions during the second quarter worth about $41,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Emergent BioSolutions by 22.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 4,409 shares during the period. Finally, Verus Capital Partners LLC acquired a new position in shares of Emergent BioSolutions in the 2nd quarter valued at about $68,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on EBS shares. Benchmark increased their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Rodman & Renshaw reiterated a "buy" rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th. Finally, StockNews.com downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th.

Emergent BioSolutions Stock Down 1.5 %

Shares of EBS stock traded down $0.14 during trading hours on Friday, reaching $9.01. The company had a trading volume of 1,045,164 shares, compared to its average volume of 1,533,003. The company has a market capitalization of $488.20 million, a P/E ratio of -2.20 and a beta of 1.59. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions Inc. has a twelve month low of $1.42 and a twelve month high of $15.10. The stock's fifty day simple moving average is $9.38 and its 200 day simple moving average is $8.57.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.